MedPath

Prasugrel

Generic Name
Prasugrel
Brand Names
Effient, Efient, Prasugrel Viatris (previously Prasugrel Mylan)
Drug Type
Small Molecule
Chemical Formula
C20H20FNO3S
CAS Number
150322-43-3
Unique Ingredient Identifier
34K66TBT99
Background

Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversibly binds to P2Y12 type ADP receptors on platelets thus preventing activation of the GPIIb/IIIa receptor complex. As a result, inhibition of ADP-mediated platelet activation and aggregation occurs. Prasugrel was developed by Daiichi Sankyo Co. and is currently marketed in the United States and Canada in cooperation with Eli Lilly and Company for acute coronary syndromes planned for percutaneous coronary intervention (PCI). FDA approved in 2009.

Indication

用于心力衰竭、卒中、不稳定心绞痛等心脑血管疾病以及有急性冠状动脉综合征需要进行经皮冠脉介入术的患者。

Associated Conditions
Cardiovascular Events
Associated Therapies
-
Clinical Trials
Related News

Comparison of Ticagrelor vs. Prasugrel on Inflammation, Arterial Stiffness, Endothelial Function, and Circulating Endothelial Progenitor Cells in Diabetic Patients With Non-ST Elevation Acute Coronary Syndrome (NSTE-ACS) Requiring Coronary Stenting

Phase 4
Completed
Conditions
Acute Coronary Syndrome
Interventions
Drug: Ticagrelor
Drug: Prasugrel
First Posted Date
2015-07-01
Last Posted Date
2019-04-25
Lead Sponsor
Korea University Anam Hospital
Target Recruit Count
60
Registration Number
NCT02487732
Locations
🇰🇷

Korea University Anam Hospital, Seoul, Korea, Republic of

Reducing Micro Vascular Dysfunction in Acute Myocardial Infarction by Ticagrelor

Phase 4
Conditions
Myocardial Infarction
Interventions
Drug: Prasugrel
Drug: Ticagrelor
First Posted Date
2015-04-21
Last Posted Date
2018-05-03
Lead Sponsor
Amsterdam UMC, location VUmc
Target Recruit Count
110
Registration Number
NCT02422888
Locations
🇳🇱

VU University Medical Center, Amsterdam, Noord-Holland, Netherlands

P3AMI Antiplatelet Trial

Phase 4
Completed
Conditions
Heart Attack
Interventions
Drug: Prasugrel
Drug: Clopidogrel
Drug: ticagrelor
First Posted Date
2015-03-03
Last Posted Date
2020-02-10
Lead Sponsor
The Royal Wolverhampton Hospitals NHS Trust
Target Recruit Count
87
Registration Number
NCT02376283
Locations
🇬🇧

The Royal Wolverhampton NHS Trust, Wolverhampton, West Midlands, United Kingdom

High "on Treatment" Platelet Reactivity in the Intensive Care Unit

First Posted Date
2014-11-07
Last Posted Date
2019-08-20
Lead Sponsor
Medical University of Vienna
Target Recruit Count
200
Registration Number
NCT02285751
Locations
🇦🇹

General Hospital, Vienna, Austria

Ticagrelor and Endothelial Function

Phase 4
Conditions
Antiplatelet Agents; Endothelial Function; Pleotropic Effects
Interventions
Drug: prasugrel
Drug: ticagrelor
First Posted Date
2014-10-10
Last Posted Date
2014-10-10
Lead Sponsor
Hotel Dieu de France Hospital
Target Recruit Count
20
Registration Number
NCT02261922
Locations
🇱🇧

Hotel Dieu de France Hospital, Achrafieh, Beirut, Lebanon

Study of Platelet Function After Administration of Aspirin Versus Lysine Acetylsalicylate

Phase 1
Completed
Conditions
Adverse Effect of Antithrombotic Drugs
Interventions
Drug: acetylsalicylic acid
Drug: lysine acetylsalicylate
Drug: prasugrel
First Posted Date
2014-09-17
Last Posted Date
2014-09-17
Lead Sponsor
David Vivas
Target Recruit Count
30
Registration Number
NCT02243137
Locations
🇪🇸

Hospital Clínico San Carlos, Madrid, Spain

Sampling P2Y12 Receptor Inhibition With Prasugrel and Ticagrelor in Patients Submitted to Thrombolysis

Phase 4
Completed
Conditions
Acute Coronary Syndrome
Platelet Function
Interventions
Drug: Prasugrel
Drug: Ticagrelor
First Posted Date
2014-08-13
Last Posted Date
2017-05-23
Lead Sponsor
Federal University of São Paulo
Target Recruit Count
50
Registration Number
NCT02215993
Locations
🇧🇷

Federal University of São Paulo, São Paulo, Brazil

Pharmacological Effects of Crushing Prasugrel in STEMI Patients

Phase 4
Completed
Conditions
Coronary Artery Disease
Interventions
Drug: prasugrel
First Posted Date
2014-08-08
Last Posted Date
2016-12-28
Lead Sponsor
University of Florida
Target Recruit Count
52
Registration Number
NCT02212028
Locations
🇺🇸

University of Florida, Jacksonville, Florida, United States

Clinical Trial to Characterize Pharmacokinetic-pharmacodynamic (PKPD) of Prasugrel 10 mg or 30 mg in Healthy Volunteers

Phase 1
Conditions
Healthy
Interventions
Drug: prasugrel
First Posted Date
2014-03-03
Last Posted Date
2014-03-04
Lead Sponsor
Asan Medical Center
Target Recruit Count
8
Registration Number
NCT02075268
Locations
🇰🇷

Asan Medical Center, Seoul, Korea, Republic of

A Pharmacodynamic Study Comparing Prasugrel Versus Ticagrelor in Patients Undergoing PCI With CYP2C19 Loss-of-function:

Phase 4
Completed
Conditions
Coronary Artery Disease
Interventions
Drug: Prasugrel
Drug: Ticagrelor
First Posted Date
2014-02-19
Last Posted Date
2020-09-16
Lead Sponsor
University of Florida
Target Recruit Count
65
Registration Number
NCT02065479
Locations
🇺🇸

University of Florida, Jacksonville, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy